Voya Investment Management LLC Sells 12,213 Shares of Illumina, Inc. $ILMN

Voya Investment Management LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 92,455 shares of the life sciences company's stock after selling 12,213 shares during the quarter. Voya Investment Management LLC owned approximately 0.06% of Illumina worth $7,335,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ILMN. Moors & Cabot Inc. grew its stake in Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after buying an additional 145 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in Illumina by 3.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after purchasing an additional 164 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its position in Illumina by 0.9% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,362 shares of the life sciences company's stock valued at $1,774,000 after purchasing an additional 207 shares during the last quarter. Probity Advisors Inc. boosted its stake in Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after purchasing an additional 224 shares in the last quarter. Finally, Rise Advisors LLC grew its holdings in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after purchasing an additional 224 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research reports. Canaccord Genuity Group upped their price target on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research report on Friday, August 1st. Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a research note on Friday, July 11th. Citigroup cut shares of Illumina from a "hold" rating to a "strong sell" rating and dropped their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Barclays upped their price objective on Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Finally, Daiwa America cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $123.06.

Illumina Price Performance

Illumina stock opened at $100.87 on Thursday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $15.50 billion, a P/E ratio of 12.77, a PEG ratio of 2.28 and a beta of 1.43. The business has a 50-day moving average of $99.65 and a 200-day moving average of $88.78. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the firm earned $0.36 EPS. Illumina's quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.